Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Mallinckrodt
AstraZeneca
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GS-9674

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug GS-9674?

GS-9674 is an investigational drug.

There have been 10 clinical trials for GS-9674. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2019.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].

There are seven US patents protecting this investigational drug and ninety-four international patents.

Recent Clinical Trials for GS-9674
TitleSponsorPhase
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)Novo Nordisk A/SPhase 2
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 2
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisGilead SciencesPhase 1

See all GS-9674 clinical trials

Clinical Trial Summary for GS-9674

Top disease conditions for GS-9674
Top clinical trial sponsors for GS-9674

See all GS-9674 clinical trials

US Patents for GS-9674

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-9674   Start Trial FXR agonists and methods for making and using Salk Institute for Biological Studies (La Jolla, CA)   Start Trial
GS-9674   Start Trial FXR (NR1H4) binding and activity modulating compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
GS-9674   Start Trial FXR (NR1H4) modulating compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-9674   Start Trial FXR (NR1H4) binding and activity modulating compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-9674

Drugname Country Document Number Estimated Expiration Related US Patent
GS-9674 Australia 2015229072 2034-03-13   Start Trial
GS-9674 Canada 2942403 2034-03-13   Start Trial
GS-9674 European Patent Office 3116878 2034-03-13   Start Trial
GS-9674 Japan 2017510572 2034-03-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Medtronic
Baxter
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.